---
canonical_name: Oxaloacetate
alternate_names: OAA, Oxaloacetic Acid, Anhydrous Enol-Oxaloacetate, AEO, 2-Oxosuccinic Acid, benaGene
canonical_topic: Oxaloacetate for Health & Longevity
short_topic_lc: oxaloacetate
creation_date: 2026-0626-0005
creator_ai_fullname: Opus 4.8
---

# Oxaloacetate for Health & Longevity
<section id="top" markdown="1"></section>

Evidence Review created on 06/26/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** OAA, Oxaloacetic Acid, Anhydrous Enol-Oxaloacetate, AEO, 2-Oxosuccinic Acid, benaGene


## Motivation

<!-- This motivation section was written last, after the rest of the document was completed, so that it accurately reflects the full scope of the review. -->

Oxaloacetate (also called oxaloacetic acid) is a small molecule that sits at the center of the body's energy factory. Every cell uses it inside a chemical loop that turns food into usable fuel, and it also helps balance the signals that tell cells when energy is plentiful or scarce. Because of this central role, a stabilized supplement form has drawn interest from people seeking to support energy, brain health, and the body's response to aging.

The interest grew after a laboratory study found that feeding oxaloacetate to a tiny worm made it live longer through the same internal pathways triggered by eating less. That finding positioned it as a compound that may copy some of the effects of cutting calories without the hunger. Since then, most human testing has focused not on aging itself but on relieving the deep, lasting fatigue of chronic fatigue syndrome and post-COVID illness.

This review examines what oxaloacetate is, how it is thought to work, and what the evidence shows for its proposed benefits and risks. It weighs the animal longevity signal against the limited, largely single-company human data, and looks at dosing, safety, and the practical questions worth answering.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-quality, accessible overviews that discuss oxaloacetate supplementation and its proposed role in energy metabolism, fatigue, and longevity.

<!-- A real-time search was performed across general web search and the platforms of the priority experts (Rhonda Patrick/foundmyfitness.com, Peter Attia/peterattiamd.com, Andrew Huberman/hubermanlab.com, Chris Kresser/chriskresser.com, Life Extension/lifeextension.com). None of the five priority experts has published dedicated content on oxaloacetate supplementation as of the creation date; the items below are the strongest available high-level overviews from other credible sources. -->

* [Oxaloacetate: the Best Mitochondrial Supplement for ME/CFS (and Long COVID?)](https://www.healthrising.org/blog/2021/10/06/oxaloacetate-mitochondrial-supplement-chronic-fatigue-long-covid/) - Cort Johnson

  A detailed, accessible deep-dive into the proposed mitochondrial mechanism of oxaloacetate and the rationale for its use in fatiguing conditions, written for a knowledgeable patient and longevity audience.

* [Oxaloacetate: Can This Miracle Molecule Enhance Longevity, Boost Brain Health, and More?](https://www.jillcarnahan.com/2021/10/06/oxaloacetate-can-this-miracle-molecule-enhance-longevity-boost-brain-health-and-more/) - Jill Carnahan

  A functional-medicine physician's accessible overview connecting oxaloacetate's caloric-restriction-mimicking and mitochondrial mechanisms to its proposed longevity, brain-health, and fatigue applications, written for a health-optimizing reader.

* [Deep Dive: Oxaloacetate for Fatigue Reduction](https://batemanhornecenter.org/deep-dive-oxaloacetate-for-fatigue-reduction/) - Rebecca Handler

  A clinic-authored review from a leading ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) research center (a trial collaborator) that summarizes the dosing, expected magnitude of benefit, and practical considerations for fatigue management.

* [Oxaloacetate supplementation increases lifespan in Caenorhabditis elegans through an AMPK/FOXO-dependent pathway](https://pubmed.ncbi.nlm.nih.gov/19793063/) - Williams et al., 2009

  The foundational primary-research paper establishing oxaloacetate as a possible caloric-restriction mimic, showing lifespan extension in worms through energy-sensing and longevity-transcription-factor pathways.

* [Oxaloacetate: A Compound with Benefits Similar to a Ketogenic Diet and Calorie Restriction](https://www.buesingnaturopathic.com/oxaloacetate/) - Buesing

  A naturopathic clinician's overview connecting the longevity and metabolic mechanisms of oxaloacetate to its supplement use, written in accessible language for a health-optimizing reader.

*Note: None of the five priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine) currently publishes dedicated oxaloacetate content, so this list draws on other credible sources; wikis and product-marketing pages were excluded.*


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool. No dedicated "Oxaloacetate" supplement article exists, but a primary dedicated page for the compound exists under "Oxaloacetic acid". -->

[Oxaloacetic acid](https://grokipedia.com/page/Oxaloacetic_acid)

The Grokipedia entry covers the compound's chemistry, its central role in the citric acid cycle and gluconeogenesis, and its biochemical context, providing background that complements the supplement-focused discussion in this review.


## Examine

<!-- examine.com was searched directly using the browser tool. A dedicated oxaloacetate page exists. -->

[Oxaloacetate](https://examine.com/supplements/oxaloacetate/)

Examine's independent, citation-based monograph summarizes the human and animal evidence on oxaloacetate for fatigue, metabolism, and cognition, with conservative grading of the strength of each claim.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool. ConsumerLab does not publish a dedicated product-testing review for oxaloacetate; it is addressed within its broader energy/fatigue supplement answers rather than as a standalone monograph. -->

No dedicated ConsumerLab review article exists for oxaloacetate.


## Systematic Reviews

This section lists the systematic reviews and meta-analyses that address oxaloacetate supplementation in humans.

* [Dietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/39940333/) - Dorczok et al., 2025

  This PRISMA-based systematic review of 14 supplement trials (809 participants) identifies oxaloacetate among the interventions showing significant fatigue reduction, while cautioning that small sample sizes, high risk of bias, and missing data prevent firm conclusions.

<!-- An independent real-time PubMed search for "oxaloacetate AND (systematic review OR meta-analysis)" and "oxaloacetate supplementation human" was performed. Only one systematic review directly evaluating oxaloacetate supplementation in humans was found (Dorczok et al., 2025); other hits concerned unrelated topics (oxaliplatin chemotherapy, transaminase enzymes). No meta-analysis pooling oxaloacetate supplementation outcomes exists as of the current date. -->


## Mechanism of Action

Oxaloacetate is a four-carbon keto-acid and a central intermediate of the citric acid cycle (also called the Krebs cycle, the chemical loop that extracts energy from food inside mitochondria, the cell's power plants). It combines with acetyl-CoA to form citrate, making it the molecule that "primes" each turn of the cycle, and it is also a starting point for gluconeogenesis (the body's manufacture of new glucose).

The leading mechanistic explanation for its supplement effects is that supplemental oxaloacetate shifts the cell's redox balance. In the cytoplasm, oxaloacetate is converted to malate by the enzyme malate dehydrogenase, a reaction that consumes NADH and raises the ratio of NAD⁺ to NADH. A higher NAD⁺/NADH ratio is itself a signal of low energy availability and activates AMPK (AMP-activated protein kinase, a master energy sensor that switches on when fuel is scarce) and the FOXO/DAF-16 family of longevity transcription factors (proteins that turn on stress-resistance and maintenance genes). This is the same signaling axis engaged by caloric restriction, which is why oxaloacetate is described as a caloric-restriction mimic.

A second proposed mechanism is direct support of mitochondrial energy production and mitochondrial biogenesis (the making of new mitochondria), alongside a reduction in neuro-inflammation and modulation of brain glutamate. In cancer-focused preclinical work, oxaloacetate has been reported to inhibit lactate dehydrogenase A and blunt the Warburg effect (the tendency of tumor cells to favor glucose fermentation), though this is mechanistic and not established in humans.

A competing mechanistic view questions whether oral oxaloacetate survives digestion and reaches tissues intact. Oxaloacetate is chemically unstable in water, decomposing to pyruvate; supplement forms address this with a thermally stabilized anhydrous enol form combined with ascorbic acid (vitamin C). Skeptics argue that any benefit may stem from downstream metabolites (malate, pyruvate, aspartate) or from the ascorbate, rather than from intact oxaloacetate reaching cells — a point unresolved by current human pharmacokinetic data, which show only small, transient rises in plasma levels.

As a non-pharmaceutical metabolite, oxaloacetate does not have a conventional drug profile, but key properties relevant to supplementation are: a very short plasma half-life (on the order of minutes for the free acid), no defined receptor selectivity, distribution governed by ordinary metabolite transport, and metabolism through the citric acid cycle and transamination (conversion to aspartate via aspartate aminotransferase) rather than through cytochrome P450 enzymes.


## Historical Context & Evolution

Oxaloacetate was characterized in the early twentieth century as a core component of the citric acid cycle, the pathway Hans Krebs described in 1937. For decades it was studied purely as a biochemical intermediate, not as anything a person might take.

Its emergence as a supplement traces to longevity research. In 2009, a laboratory study reported that oxaloacetate extended lifespan in the roundworm *Caenorhabditis elegans* through AMPK and FOXO signaling — the pathways that mediate the life-extending effects of dietary restriction. One of the authors, Alan Cash, subsequently commercialized a thermally stabilized form (marketed as benaGene) and founded the company that has driven most subsequent human research. This origin is important for interpreting the evidence base, which remains closely tied to a single commercial sponsor.

The original animal findings have not been dismissed, but their relevance to humans remains open. The worm result is a genuine, reproduced observation within its model; what changed over time is the recognition that lifespan effects in invertebrates frequently fail to translate to mammals, and that no rodent or human lifespan data for oxaloacetate exist. Human research then pivoted away from aging toward specific conditions — Alzheimer's disease, Parkinson's disease, gliomas, and most prominently chronic fatigue syndrome and long COVID — where the metabolic and mitochondrial rationale could be tested against measurable endpoints. The current standing is therefore one of a promising mechanistic story with strong invertebrate longevity data and growing but conflict-laden human fatigue data, rather than a settled longevity intervention.


## Expected Benefits

A dedicated search of clinical trial registries, PubMed, and expert and clinical sources was performed to assemble the complete benefit profile below. Benefits are graded by the strength of the underlying human evidence, and almost all human data come from studies sponsored by the sole manufacturer — a conflict of interest carried into every grade below.


### Medium 🟩 🟩

#### Reduction of Fatigue in Chronic Fatigue Syndrome and Long COVID

This is the most studied human benefit. Supplemental oxaloacetate is proposed to restore depleted cellular energy substrate and support mitochondrial function in conditions marked by impaired energy metabolism. The evidence basis is one randomized, double-blind controlled trial (RESTORE ME, 82 participants) plus an earlier non-randomized controlled trial, both showing fatigue reductions greater than 25% from baseline versus roughly 10% in controls, with about 40% of treated participants classified as "enhanced responders." The important nuance is that all of these trials were conducted or sponsored by the manufacturer, and the evidence base has drawn methodological criticism (small samples, high risk of bias); independent replication is absent.

**Magnitude:** Roughly 25–33% reduction in Chalder Fatigue Scale scores from baseline at 6 weeks to 3 months; up to ~46% in long COVID; "enhanced responders" averaged ~63%.


### Low 🟩

#### Mimicry of Caloric Restriction / Longevity Signaling

Oxaloacetate is proposed to activate the same AMPK and FOXO pathways engaged by eating less, potentially supporting cellular maintenance and stress resistance. The evidence basis is the foundational *C. elegans* lifespan study and supporting cell-signaling work showing a shift in the NAD⁺/NADH ratio; there are no mammalian lifespan studies and no human longevity outcomes. This benefit is mechanistically plausible and supported by a reproduced invertebrate result (worm lifespan extension on the order of 13–25% in the original model), but its translation to human healthspan is unproven.

**Magnitude:** Not quantified in available studies.

#### Improved Glucose Regulation and Insulin Sensitivity

By feeding into gluconeogenesis and activating AMPK, oxaloacetate has been proposed to lower blood glucose and improve insulin signaling. The evidence basis is limited older human and animal work suggesting oral oxaloacetate salts (100–1,000 mg) can reduce blood glucose, plus the mechanistic AMPK link shared with metformin. Data are sparse, dated, and not from rigorous modern trials, so the effect size in healthy or pre-diabetic adults is uncertain.

**Magnitude:** Not quantified in available studies.

#### Support of Brain Energy Metabolism and Neuroprotection

Oxaloacetate is proposed to enhance brain mitochondrial biogenesis, scavenge excess glutamate, and reduce neuro-inflammation, which motivated trials in Alzheimer's and Parkinson's disease. The evidence basis is early-phase human safety and pharmacokinetic trials (e.g., the Trial of Oxaloacetate in Alzheimer's Disease) plus preclinical neuroprotection data; these established tolerability and target engagement signals but were not powered to demonstrate cognitive benefit. A breast-cancer-survivor trial examined cognitive complaints with results not yet establishing efficacy.

**Magnitude:** Not quantified in available studies.


### Speculative 🟨

#### Adjunctive Anti-Tumor / Anti-Glioma Activity

Preclinical work suggests oxaloacetate may inhibit lactate dehydrogenase A, blunt the Warburg effect, and reduce glutamate-driven tumor growth, prompting interest as an add-on to standard glioblastoma therapy. The basis is mechanistic and preclinical only, together with a small phase 2 glioblastoma trial of unknown outcome; no controlled human efficacy data exist, so this remains hypothesis-generating.

#### Emotional Premenstrual Symptom Relief

A small completed trial explored oxaloacetate for mood, anxiety, and stress associated with emotional premenstrual syndrome, on the rationale of metabolic and glutamate modulation. The basis is a single small study without robust published efficacy data, making any benefit speculative.


## Benefit-Modifying Factors

The following factors may influence how much benefit an individual derives from oxaloacetate.

* **Baseline oxaloacetate and energy status:** Fatigue trials note that plasma oxaloacetate is lower in ME/CFS patients, suggesting that individuals with depleted baseline levels or impaired mitochondrial function may respond more than metabolically healthy adults. The pronounced "enhanced responder" subgroup hints at responder heterogeneity that is not yet explained.

* **Pre-existing health conditions:** The clearest signals of benefit appear in people with a fatiguing or neurodegenerative condition rather than in healthy individuals; a healthy longevity-oriented adult may see smaller or no measurable effect because there is less metabolic deficit to correct.

* **Genetic polymorphisms:** Variants affecting AMPK signaling, FOXO3 (a longevity-associated transcription factor), or mitochondrial efficiency could plausibly modify response, but no pharmacogenetic data specific to oxaloacetate exist; this remains theoretical.

* **Sex-based differences:** Several trials enrolled predominantly women (e.g., ~74% in the fatigue cohorts) and one targeted premenstrual symptoms, but no head-to-head analysis has established sex-specific efficacy; differences are unquantified.

* **Age-related considerations:** The neurodegeneration trials enrolled older adults and established tolerability in that group, but whether older adults gain more energy or cognitive benefit than middle-aged adults is not established.


## Potential Risks & Side Effects

A dedicated search of clinical trial safety data, supplement references, and drug-information sources was performed to assemble the risk profile below. Across human trials, oxaloacetate has been consistently described as well tolerated, so most risks are low-grade or theoretical; the manufacturer-sponsored nature of the safety data is itself a limitation.


### Low 🟥

#### Gastrointestinal Upset

Mild digestive complaints, including dyspepsia (indigestion or upper-abdominal discomfort) and nausea, are the most commonly reported adverse effects in fatigue trials. The proposed mechanism is direct gastric irritation from an organic acid plus the co-formulated vitamin C. The evidence basis is adverse-event reporting in the ME/CFS and long COVID trials, where such events were non-severe and did not typically require stopping treatment. Severity is generally mild and reversible on discontinuation or with food.

**Magnitude:** Reported in a minority of participants across trials; non-severe.

#### Insomnia and Activation

Some users and trial participants report insomnia or a stimulating, "activating" effect, plausibly because enhanced energy metabolism and AMPK activity raise alertness. The evidence basis is scattered adverse-event reports in the dietary-supplement systematic review and fatigue trials. It is generally manageable by dosing earlier in the day; severity is mild and reversible.

**Magnitude:** Not quantified in available studies.


### Speculative 🟨

#### Possible Worsening of Parkinson's Disease Symptoms ⚠️ Conflicted

A small pilot trial in treated Parkinson's disease reported that more participants on oxaloacetate (7 of 18) described worsened symptoms than on placebo (1 of 15), raising a caution that this population may react unfavorably, possibly through effects on dopaminergic or glutamate signaling. The evidence is conflicted: the trial was small, the comparison was not the primary endpoint, and the broader mechanistic rationale had actually predicted benefit. Because the signal is unexplained and from a single small study, it is treated as speculative but worth flagging for anyone with Parkinson's disease.

#### Unknown Long-Term and Reproductive Safety

No long-term safety studies exist, and oxaloacetate has not been evaluated in children, pregnancy, or breastfeeding; supplement guidance advises against use in pregnancy and lactation. The basis is the simple absence of data rather than any observed harm. This is a precautionary, isolated-data concern rather than a documented adverse effect.

#### Theoretical Metabolic Acidosis or Substrate Loading at High Doses

As an organic acid feeding into central metabolism, very high intake could in theory perturb acid-base balance or amino-acid (aspartate/glutamate) pools, but no such events have been observed at the 1,000–2,000 mg doses studied. This concern is mechanistic and unobserved.


## Risk-Modifying Factors

The following factors may influence the likelihood or severity of adverse effects.

* **Pre-existing health conditions:** People with Parkinson's disease warrant particular caution given the small-trial signal of symptom worsening; those with sensitive digestion may be more prone to the gastrointestinal effects.

* **Sex-based differences:** No sex-specific safety differences have been established; trial cohorts were predominantly female, which limits the strength of any male-specific safety inference.

* **Age-related considerations:** Older adults were studied in the neurodegeneration trials without unusual adverse events, but polypharmacy in this group increases the theoretical chance of interactions and makes conservative dosing prudent.

* **Genetic polymorphisms:** No variants are known to modify oxaloacetate's safety profile; this has not been studied.

* **Baseline biomarker levels:** Individuals with impaired kidney or liver function have not been specifically studied, so those with abnormal baseline renal or hepatic markers should regard the safety data as not applicable to them.


## Key Interactions & Contraindications

Oxaloacetate has not been the subject of formal drug-interaction studies, so the items below are based on mechanism and prudent extrapolation rather than documented clinical events.

* **Glucose-lowering drugs and supplements:** Because oxaloacetate may lower blood glucose and activates AMPK (the same energy sensor targeted by metformin), combining it with antidiabetic drugs (metformin, sulfonylureas such as glipizide, insulin) or glucose-lowering supplements (berberine, alpha-lipoic acid, chromium) could have additive effects. Severity: caution; clinical consequence: possible hypoglycemia (low blood sugar). Mitigation: monitor blood glucose and adjust as needed.

* **Levodopa / Parkinson's medications:** Given the small-trial signal of symptom worsening, co-use with dopaminergic drugs (levodopa-carbidopa, dopamine agonists such as pramipexole) is a relative caution until more data exist. Severity: caution; clinical consequence: possible symptom fluctuation. Mitigation: avoid in Parkinson's disease pending further evidence.

* **Other mitochondrial / energy supplements:** Combinations with NAD⁺ precursors (NMN, NR), CoQ10, creatine, or ribose are commonly used together and are additive in intent rather than dangerous; no harmful interaction is documented. Severity: monitor; clinical consequence: none established.

* **Over-the-counter medications:** The co-formulated vitamin C is generally inert, but high combined ascorbate intake with iron supplements can increase iron absorption. Severity: monitor; clinical consequence: relevant mainly to those with iron overload conditions.

* **Populations who should avoid or use caution:** People with Parkinson's disease (symptom-worsening signal); pregnant or breastfeeding individuals and children (no safety data); and anyone on tightly titrated glucose-lowering therapy without monitoring. No absolute contraindication is established for the general adult population.


## Risk Mitigation Strategies

The following strategies address the specific risks identified above.

* **Start low and titrate:** Begin at a low dose (e.g., 100–500 mg daily) and increase gradually toward studied doses, which mitigates gastrointestinal upset and lets activating or sleep effects surface before higher exposure.

* **Take with food and earlier in the day:** Taking oxaloacetate with a meal mitigates dyspepsia and nausea, and dosing in the morning or early afternoon mitigates insomnia and the activating effect.

* **Monitor blood glucose if on antidiabetic therapy:** For anyone using metformin, sulfonylureas, insulin, or potent glucose-lowering supplements, periodic self-monitoring of blood glucose mitigates the additive hypoglycemia risk.

* **Avoid in Parkinson's disease pending evidence:** Given the small-trial worsening signal, individuals with Parkinson's disease should avoid oxaloacetate until controlled data clarify the effect.

* **Avoid in pregnancy, breastfeeding, and childhood:** Because no safety data exist for these groups, abstaining mitigates the unknown reproductive and developmental risk.

* **Reassess after a defined trial period:** Because benefit appears concentrated in responders, setting a 6–12 week trial with a planned stop-if-no-benefit decision mitigates unnecessary long-term exposure of unknown safety.


## Therapeutic Protocol

The protocols below reflect how oxaloacetate has been used in clinical trials and by clinicians working in fatigue and longevity contexts. No formal medical guideline exists, and most dosing derives from the manufacturer-sponsored trial program.

* **Standard fatigue protocol (as used in trials):** The randomized controlled ME/CFS trial used 2,000 mg per day (commonly split as 1,000 mg twice daily); earlier dose-escalation work ranged from 500 mg twice daily up to 1,000 mg three times daily, with benefit increasing across that range. This protocol, developed within the Terra Biological / Bateman Horne Center trial program, is the best-characterized approach.

* **Longevity / general-use protocol:** Outside fatigue research, lower daily doses (often 100–200 mg, the marketed benaGene dose) are commonly used on the rationale that they may engage caloric-restriction-mimicking signaling with minimal side effects; this lower-dose use is not supported by outcome trials and is extrapolated from the mechanism.

* **Competing approaches:** A conventional view holds that any benefit is best pursued through caloric restriction or intermittent fasting directly, with oxaloacetate as an unproven shortcut; an integrative/biohacking view positions it within a stack of mitochondrial-support supplements. Neither is framed here as the default.

* **Best time of day:** Morning or early-afternoon dosing is generally preferred to avoid sleep disruption from the activating effect; split dosing across the day is used in trials.

* **Half-life:** Free oxaloacetate has a very short plasma half-life (minutes), which is the rationale for divided daily dosing rather than a single dose.

* **Single vs. split dosing:** Trials used split dosing (twice or three times daily); split dosing is the norm given the short half-life and to smooth gastrointestinal tolerability.

* **Genetic polymorphisms:** No pharmacogenetic dosing guidance exists; variants in AMPK or FOXO3 pathways are of theoretical interest only.

* **Sex-based differences:** No sex-specific dosing has been established, despite predominantly female trial cohorts.

* **Age-related considerations:** Older adults tolerated studied doses in neurodegeneration trials; conservative starting doses are reasonable given polypharmacy.

* **Baseline biomarker levels:** Lower baseline plasma oxaloacetate (seen in ME/CFS) may predict greater response, but baseline testing is not routinely available or validated for dosing.

* **Pre-existing health conditions:** Those with metabolic or fatiguing conditions are the populations in whom benefit has been observed; healthy adults should expect uncertain effects.


## Discontinuation & Cycling

* **Lifelong vs. short-term:** Oxaloacetate is not established as a lifelong therapy; trials ran for 6 weeks to 3 months, and continued benefit beyond those windows is unstudied. A defined trial period followed by reassessment is the most evidence-aligned approach.

* **Withdrawal effects:** No withdrawal syndrome has been reported; because it is a natural metabolite, abrupt cessation is not expected to cause rebound effects, though any energy benefit would presumably fade.

* **Tapering:** No tapering protocol is required or described; the supplement can be stopped directly based on available data.

* **Cycling:** No cycling regimen has been validated. Some users cycle on the general principle of avoiding tolerance, but there is no evidence that tolerance develops or that cycling preserves efficacy.


## Sourcing and Quality

* **Stabilized form matters most:** Pure oxaloacetate is unstable in water; effective products use a thermally stabilized anhydrous enol-oxaloacetate, typically combined with ascorbic acid (vitamin C) to preserve it. Products not specifying a stabilized form may degrade to pyruvate before use.

* **Third-party testing:** Because this is a dietary supplement, looking for third-party testing or certification (e.g., NSF, USP, or independent certificate-of-analysis) helps verify identity and purity, which is not guaranteed by label alone.

* **Reputable sources:** The original patented, trial-used material is marketed as benaGene (Terra Biological); this is also the dominant source in the research, which is relevant to both quality and conflict-of-interest interpretation. Other brands exist but vary in whether they disclose stabilization and testing.

* **Formulation details:** Standardized capsule doses (commonly 100 mg or 250 mg) with disclosed vitamin C content allow accurate dosing; bulk powders of unstabilized oxaloacetate are generally a poor choice due to instability.


## Practical Considerations

* **Time to effect:** Fatigue trials measured benefit over 6 weeks, with dose-dependent improvement; users should not expect an immediate effect and should allow several weeks before judging response.

* **Common pitfalls:** Expecting benefit in a metabolically healthy person (where the deficit being corrected may not exist), using unstabilized product that has degraded, dosing too late in the day and disrupting sleep, and over-interpreting the longevity claim, which rests on worm data only.

* **Regulatory status:** Oxaloacetate is sold as a dietary supplement, not an approved drug; it has been used as an investigational agent in trials and has received orphan/FDA designations in specific disease contexts (e.g., glioblastoma), but it is not an approved treatment for fatigue, aging, or any condition.

* **Cost and accessibility:** It is readily available without prescription but is relatively expensive at the higher (trial-level) doses, since 2,000 mg/day requires many capsules; the lower 100–200 mg "longevity" dose is more affordable but less evidence-backed.


## Interaction with Foundational Habits

* **Sleep:** Indirect, potentially disruptive. Through enhanced energy metabolism and AMPK activation, oxaloacetate can be activating; the practical consideration is to dose in the morning or early afternoon to avoid insomnia, and to monitor sleep when starting.

* **Nutrition:** Potentiating with caloric restriction or low-carbohydrate/ketogenic eating. Because oxaloacetate is proposed to mimic caloric-restriction signaling, it is mechanistically aligned with fasting and carbohydrate-restricted diets; taking it with food also blunts gastrointestinal upset. No specific nutrient depletion is documented.

* **Exercise:** Direct and complementary. Exercise itself activates AMPK, so oxaloacetate's proposed mechanism overlaps with training adaptations; there is no evidence it blunts hypertrophy, and no specific workout-timing requirement is established, though morning dosing pairs naturally with training.

* **Stress management:** Indirect. By engaging FOXO-linked stress-resistance pathways, oxaloacetate is theorized to support cellular stress handling, but there is no human evidence that it alters cortisol or the psychological stress response; standard stress-management practices remain the primary lever.


## Monitoring Protocol & Defining Success

Because oxaloacetate is an over-the-counter metabolite with a benign observed safety profile, formal laboratory monitoring is limited; the focus is on tracking the targeted outcome (energy/fatigue) and a few metabolic safety markers, especially in people on interacting therapy. Baseline testing before starting establishes a reference point for the markers below, and ongoing monitoring is reasonable at roughly 6–12 weeks after starting (to coincide with the expected onset of any benefit) and then every 6–12 months for those continuing long-term.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|----------------|
| Fasting glucose | 70–90 mg/dL | Detects the additive glucose-lowering effect, especially with antidiabetic agents | Fasting sample; conventional reference up to 99 mg/dL is broader than the functional target |
| HbA1c | < 5.4% | Tracks longer-term glucose impact of any insulin-sensitizing effect | HbA1c (glycated hemoglobin, a measure of average blood sugar) needs no fasting; reflects ~3-month average |
| Fasting insulin | 2–5 µIU/mL | Assesses whether insulin sensitivity improves over time | Fasting sample; best paired with glucose for HOMA-IR (a simple calculated index of insulin resistance) |
| Comprehensive metabolic panel (liver and kidney markers) | ALT/AST < 25 U/L; eGFR > 90 mL/min/1.73m² | General safety surveillance for an organic-acid metabolite, particularly at higher doses | ALT and AST (liver enzymes), eGFR (estimated glomerular filtration rate, a measure of kidney function); conventional ranges are wider (ALT up to ~40 U/L); fasting preferred |
| hs-CRP | < 1.0 mg/L | Tracks any anti-inflammatory effect claimed mechanistically | hs-CRP (high-sensitivity C-reactive protein, a general marker of inflammation); avoid testing during acute illness |

* **Qualitative markers** to track alongside labs:

  - Physical fatigue and exertion tolerance (e.g., a validated fatigue scale or a simple daily rating)
  - Mental fatigue, focus, and cognitive clarity
  - Sleep quality and whether dosing time affects it
  - Day-to-day energy and post-exertional recovery
  - Mood and stress resilience


## Emerging Research

The oxaloacetate research landscape is dominated by a small number of trials, most tied to a single sponsor, spanning fatigue, neurodegeneration, and oncology. Both supportive and skeptical lines of inquiry are active.

* **Completed randomized fatigue trial (could strengthen the case):** The RESTORE ME trial ([NCT05273372](https://clinicaltrials.gov/study/NCT05273372), ~82 participants, randomized double-blind) reported a significant fatigue reduction and is the strongest human result to date; independent replication outside the sponsor is the key open need.

* **Long COVID randomized trial (could strengthen or weaken the case):** The REGAIN trial ([NCT05840237](https://clinicaltrials.gov/study/NCT05840237), ~70 participants) evaluated oxaloacetate for long COVID fatigue using the Chalder Fatigue Score; results will test whether the open-label long COVID signal holds under randomization.

* **Glioblastoma trial (speculative oncology direction):** A phase 2 trial of anhydrous enol-oxaloacetate in new glioblastoma ([NCT04450160](https://clinicaltrials.gov/study/NCT04450160), ~80 participants, overall survival endpoint) tests the preclinical anti-Warburg rationale; its status is uncertain and outcomes are not yet established.

* **Neurodegeneration safety and target engagement:** Early trials in Alzheimer's disease ([NCT02593318](https://clinicaltrials.gov/study/NCT02593318)) and ALS ([NCT04204889](https://clinicaltrials.gov/study/NCT04204889), amyotrophic lateral sclerosis, a progressive motor-neuron disease) established tolerability and pharmacokinetics; future adequately powered efficacy trials could either support or undercut the neuroprotection hypothesis.

* **Mechanistic and independent scrutiny (could weaken the case):** The single available systematic review by [Dorczok et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39940333/) flags high risk of bias across supplement trials including oxaloacetate, and the foundational longevity claim still rests only on the [Williams et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19793063/) worm study; mammalian lifespan and independent human pharmacokinetic work are the decisive future tests.


## Conclusion

Oxaloacetate is a natural energy molecule, sold as a stabilized supplement, that sits at the heart of how cells turn food into fuel and helps balance the signals that respond to eating less. Its appeal for longevity rests largely on a single laboratory study in worms, where it extended lifespan through the same pathways triggered by cutting calories. That finding is real but has never been shown to carry over to mammals or people, so the longevity case remains a promising idea rather than a demonstrated effect.

The strongest human evidence is for easing the deep fatigue of chronic fatigue syndrome and long COVID, where a small randomized study and earlier trials report meaningful improvement, with a subset of people responding strongly. The most important caveat is that nearly all of this research comes from the company that makes the product, so the evidence base is narrow and tied to a single interested party. Other proposed uses — steadier blood sugar, brain support, and add-on cancer therapy — are early or unproven, and a small study raised a caution for people with Parkinson's disease.

The supplement appears well tolerated, with mostly mild digestive or sleep effects and unknown long-term safety. Overall, the evidence is limited, encouraging in one narrow area, and clouded by who funded it.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**

<section id="iterations" markdown="1"></section>